To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...

Cell death triggered by GPX4 loss was slowed in cell cultures and in mouse model using compounds that specifically inhibit ferroptosis.

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...

Mirum inks 620M deal to acquire Bluejay Therapeutics, adding brelovitug, a phase 3 hepatitis delta drug, to its liver disease pipeline.

Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...

CANbridge Pharmaceuticals Inc. ( ($HK:1228) ) has shared an update. CANbridge Pharmaceuticals Inc. announced that its enzyme replacement therapy, ...

When it comes to the hardest-working organs, the liver plays a key role. From working as a natural detoxifier to filtering ...

Mirum Pharmaceuticals Inc. has agreed to acquire Bluejay Therapeutics, a privately held biotechnology company focused on ...

Kamada ends its Phase 3 inhaled AAT trial after a futility analysis but maintains 2025 guidance and forecasts double-digit growth in 2026.

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...